Celgene Corp /de/ - Net Worth and Insider Trading

Celgene Corp /de/ Net Worth

The estimated net worth of Celgene Corp /de/ is at least $1.8 Billion dollars as of 2024-11-05. Celgene Corp /de/ is the 10% Owner of Acceleron Pharma Inc and owns about 7,008,510 shares of Acceleron Pharma Inc (XLRN) stock worth over $1.3 Billion. Celgene Corp /de/ is the 10% Owner of Agios Pharmaceuticals Inc and owns about 7,121,658 shares of Agios Pharmaceuticals Inc (AGIO) stock worth over $331 Million. Celgene Corp /de/ is also the 10% Owner of CRISPR Therapeutics AG and owns about 3,722,534 shares of CRISPR Therapeutics AG (CRSP) stock worth over $186 Million. Besides these, Celgene Corp /de/ also holds Adynxx Inc (ADYX) . Details can be seen in Celgene Corp /de/'s Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Celgene Corp /de/ has not made any transactions after 2020-07-09 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Celgene Corp /de/

Celgene Corp /de/ Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Celgene Corp /de/ owns 10 companies in total, including Acceleron Pharma Inc (XLRN) , Agios Pharmaceuticals Inc (AGIO) , and Sutro Biopharma Inc (STRO) among others .

Click here to see the complete history of Celgene Corp /de/’s form 4 insider trades.

Insider Ownership Summary of Celgene Corp /de/

Ticker	Comapny	Transaction Date	Type of Owner
XLRN	Acceleron Pharma Inc	2020-07-09	10 percent owner
AGIO	Agios Pharmaceuticals Inc	2019-11-12	10 percent owner
STRO	Sutro Biopharma Inc	2018-09-26	10 percent owner
		2018-03-05	10 percent owner
		2017-12-04	10 percent owner
		2017-04-11	10 percent owner
		2017-01-26	10 percent owner
		2014-07-08	10 percent owner
		2013-05-30	10 percent owner
		2005-03-31	10 percent owner

Celgene Corp /de/ Latest Holdings Summary

Celgene Corp /de/ currently owns a total of 4 stocks. Among these stocks, Celgene Corp /de/ owns 7,008,510 shares of Acceleron Pharma Inc (XLRN) as of July 9, 2020, with a value of $1.3 Billion and a weighting of 70.81%. Celgene Corp /de/ owns 7,121,658 shares of Agios Pharmaceuticals Inc (AGIO) as of November 12, 2019, with a value of $331 Million and a weighting of 18.7%. Celgene Corp /de/ also owns 3,722,534 shares of CRISPR Therapeutics AG (CRSP) as of December 4, 2017, with a value of $186 Million and a weighting of 10.49%. The other 1 stocks Adynxx Inc (ADYX) have a combined weighting of 0% among all his current holdings.

Latest Holdings of Celgene Corp /de/

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
XLRN	Acceleron Pharma Inc	2020-07-09	7,008,510	178.75	1,252,771,163
AGIO	Agios Pharmaceuticals Inc	2019-11-12	7,121,658	46.47	330,943,447
CRSP	CRISPR Therapeutics AG	2017-12-04	3,722,534	49.85	185,568,320
ADYX	Adynxx Inc	2017-02-27	117,435	0.00	12

Holding Weightings of Celgene Corp /de/

Celgene Corp /de/ Form 4 Trading Tracker

According to the SEC Form 4 filings, Celgene Corp /de/ has made a total of 2 transactions in Acceleron Pharma Inc (XLRN) over the past 5 years, including 1 buys and 1 sells. The most-recent trade in Acceleron Pharma Inc is the sale of 2,241 shares on July 9, 2020, which brought Celgene Corp /de/ around $229,209.

According to the SEC Form 4 filings, Celgene Corp /de/ has made a total of 1 transactions in Agios Pharmaceuticals Inc (AGIO) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Agios Pharmaceuticals Inc is the acquisition of 403,225 shares on November 12, 2019, which cost Celgene Corp /de/ around $13 Million.

According to the SEC Form 4 filings, Celgene Corp /de/ has made a total of 0 transactions in CRISPR Therapeutics AG (CRSP) over the past 5 years. The most-recent trade in CRISPR Therapeutics AG is the sale of 1,112,446 shares on December 4, 2017, which brought Celgene Corp /de/ around $21 Million.

More details on Celgene Corp /de/'s insider transactions can be found in the Insider Trading History of Celgene Corp /de/ table.

Insider Trading History of Celgene Corp /de/

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Celgene Corp /de/ Trading Performance

GuruFocus tracks the stock performance after each of Celgene Corp /de/'s buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Celgene Corp /de/ is 10.74%. GuruFocus also compares Celgene Corp /de/'s trading performance to market benchmark return within the same time period. The performance of stocks bought by Celgene Corp /de/ within 3 months outperforms 9 times out of 14 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Celgene Corp /de/'s insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Celgene Corp /de/

Average Return

Average return per transaction

Outperforming Transactions

7 out of 14 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	9.36
Relative Return to S&P 500(%)	8.28

Celgene Corp /de/ Ownership Network

Ownership Network List of Celgene Corp /de/

No Data

Ownership Network Relation of Celgene Corp /de/

Celgene Corp /de/ Owned Company Details

What does Acceleron Pharma Inc do?

Who are the key executives at Acceleron Pharma Inc?

Celgene Corp /de/ is the 10 percent owner of Acceleron Pharma Inc. Other key executives at Acceleron Pharma Inc include EVP & Chief Commercial Officer Sujay Kango , SVP & CFO and Treasurer Kevin F Mclaughlin , and SVP & General Counsel and Sec. Adam M Veness .

Acceleron Pharma Inc (XLRN) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Acceleron Pharma Inc (XLRN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Acceleron Pharma Inc (XLRN) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Acceleron Pharma Inc (XLRN)'s detailed insider trading history can be found in Insider Trading Tracker table.

Acceleron Pharma Inc Insider Transactions

No Available Data

What does Agios Pharmaceuticals Inc do?

Who are the key executives at Agios Pharmaceuticals Inc?

Celgene Corp /de/ is the 10 percent owner of Agios Pharmaceuticals Inc. Other key executives at Agios Pharmaceuticals Inc include Chief Financial Officer Cecilia Jones , director & Chief Executive Officer Brian Goff , and Chief Medical Officer Sarah Gheuens .

Agios Pharmaceuticals Inc (AGIO) Insider Trades Summary

Over the past 18 months, Celgene Corp /de/ made no insider transaction in Agios Pharmaceuticals Inc (AGIO). Other recent insider transactions involving Agios Pharmaceuticals Inc (AGIO) include a net sale of 9,416 shares made by Washburn Theodore James Jr. , a net sale of 64,534 shares made by Brian Goff , and a net sale of 14,160 shares made by James William Burns .

In summary, during the past 3 months, insiders sold 13,633 shares of Agios Pharmaceuticals Inc (AGIO) in total and bought 0 shares, with a net sale of 13,633 shares. During the past 18 months, 252,596 shares of Agios Pharmaceuticals Inc (AGIO) were sold and 0 shares were bought by its insiders, resulting in a net sale of 252,596 shares.

Agios Pharmaceuticals Inc (AGIO)'s detailed insider trading history can be found in Insider Trading Tracker table.

Agios Pharmaceuticals Inc Insider Transactions

No Available Data

What does Sutro Biopharma Inc do?

Who are the key executives at Sutro Biopharma Inc?

Celgene Corp /de/ is the 10 percent owner of Sutro Biopharma Inc. Other key executives at Sutro Biopharma Inc include Chief Port. Strat & Alnce Ofcr Nicki Vasquez , Chief Scientific Officer Hans-peter Gerber , and Chief Business Officer Brunilda Shtylla .

Sutro Biopharma Inc (STRO) Insider Trades Summary

Over the past 18 months, Celgene Corp /de/ made no insider transaction in Sutro Biopharma Inc (STRO). Other recent insider transactions involving Sutro Biopharma Inc (STRO) include a net sale of 27,041 shares made by Brunilda Shtylla , and a net sale of 12,185 shares made by Nicki Vasquez .

In summary, during the past 3 months, insiders sold 0 shares of Sutro Biopharma Inc (STRO) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 39,226 shares of Sutro Biopharma Inc (STRO) were sold and 0 shares were bought by its insiders, resulting in a net sale of 39,226 shares.

Sutro Biopharma Inc (STRO)'s detailed insider trading history can be found in Insider Trading Tracker table.

Sutro Biopharma Inc Insider Transactions

No Available Data

What does Juno Therapeutics Inc do?

Who are the key executives at Juno Therapeutics Inc?

Celgene Corp /de/ is the 10 percent owner of Juno Therapeutics Inc. Other key executives at Juno Therapeutics Inc include director & CEO & President Hans Edgar Bishop , 10 percent owner Celgene Switzerland Llc , and President of R & D Sunil Agarwal .

Juno Therapeutics Inc (JUNO) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Juno Therapeutics Inc (JUNO) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Juno Therapeutics Inc (JUNO) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Juno Therapeutics Inc (JUNO)'s detailed insider trading history can be found in Insider Trading Tracker table.

Juno Therapeutics Inc Insider Transactions

No Available Data

What does CRISPR Therapeutics AG do?

Who are the key executives at CRISPR Therapeutics AG?

Celgene Corp /de/ is the 10 percent owner of CRISPR Therapeutics AG. Other key executives at CRISPR Therapeutics AG include Chief Business Officer Samarth Kulkarni , General Counsel and Secretary James R. Kasinger , and Chief Financial Officer Raju Prasad .

CRISPR Therapeutics AG (CRSP) Insider Trades Summary

Over the past 18 months, Celgene Corp /de/ made no insider transaction in CRISPR Therapeutics AG (CRSP). Other recent insider transactions involving CRISPR Therapeutics AG (CRSP) include a net sale of 179,630 shares made by Samarth Kulkarni , a net sale of 6,949 shares made by James R. Kasinger , and a net sale of 3,524 shares made by Raju Prasad .

In summary, during the past 3 months, insiders sold 5,382 shares of CRISPR Therapeutics AG (CRSP) in total and bought 0 shares, with a net sale of 5,382 shares. During the past 18 months, 193,469 shares of CRISPR Therapeutics AG (CRSP) were sold and 0 shares were bought by its insiders, resulting in a net sale of 193,469 shares.

CRISPR Therapeutics AG (CRSP)'s detailed insider trading history can be found in Insider Trading Tracker table.

CRISPR Therapeutics AG Insider Transactions

No Available Data

What does Adynxx Inc do?

Who are the key executives at Adynxx Inc?

Celgene Corp /de/ is the 10 percent owner of Adynxx Inc. Other key executives at Adynxx Inc include 10 percent owner David Bonderman , CHIEF MEDICAL OFFICER Donald C. Manning , and 10 percent owner Domain Partners Viii, L.p. .

Adynxx Inc (ADYX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Adynxx Inc (ADYX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Adynxx Inc (ADYX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Adynxx Inc (ADYX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Adynxx Inc Insider Transactions

No Available Data

What does Jounce Therapeutics Inc do?

Who are the key executives at Jounce Therapeutics Inc?

Celgene Corp /de/ is the 10 percent owner of Jounce Therapeutics Inc. Other key executives at Jounce Therapeutics Inc include 10 percent owner Concentra Merger Sub, Inc. , 10 percent owner Concentra Biosciences, Llc , and director & CEO and President Richard /ca/ Murray .

Jounce Therapeutics Inc (JNCE) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Jounce Therapeutics Inc (JNCE) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Jounce Therapeutics Inc (JNCE) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Jounce Therapeutics Inc (JNCE)'s detailed insider trading history can be found in Insider Trading Tracker table.

Jounce Therapeutics Inc Insider Transactions

No Available Data

What does GlobeImmune Inc do?

Who are the key executives at GlobeImmune Inc?

Celgene Corp /de/ is the 10 percent owner of GlobeImmune Inc. Other key executives at GlobeImmune Inc include other: Former 10% Owner Healthcare Ventures Vii Lp , other: Former 10% Owner John W Littlechild , and other: Former 10% Owner James H Cavanaugh .

GlobeImmune Inc (GBIM) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of GlobeImmune Inc (GBIM) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of GlobeImmune Inc (GBIM) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

GlobeImmune Inc (GBIM)'s detailed insider trading history can be found in Insider Trading Tracker table.

GlobeImmune Inc Insider Transactions

No Available Data

What does Epizyme Inc do?

Who are the key executives at Epizyme Inc?

Celgene Corp /de/ is the 10 percent owner of Epizyme Inc. Other key executives at Epizyme Inc include Chief Scientific Officer Jeffery Kutok , Chief Operating Officer Jerald Korn , and Corporate Controller Joseph Beaulieu .

Epizyme Inc (EPZM) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Epizyme Inc (EPZM) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Epizyme Inc (EPZM) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Epizyme Inc (EPZM)'s detailed insider trading history can be found in Insider Trading Tracker table.

Epizyme Inc Insider Transactions

No Available Data

What does CASI Pharmaceuticals Inc do?

Who are the key executives at CASI Pharmaceuticals Inc?

Celgene Corp /de/ is the 10 percent owner of CASI Pharmaceuticals Inc. Other key executives at CASI Pharmaceuticals Inc include director & 10 percent owner & Chairman and CEO Wei-wu He , Chief Financial Officer Weihao Xu , and President Larry Zhang .

CASI Pharmaceuticals Inc (CASI) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of CASI Pharmaceuticals Inc (CASI) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of CASI Pharmaceuticals Inc (CASI) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

CASI Pharmaceuticals Inc (CASI)'s detailed insider trading history can be found in Insider Trading Tracker table.

CASI Pharmaceuticals Inc Insider Transactions

No Available Data

Celgene Corp /de/ Mailing Address

Above is the net worth, insider trading, and ownership report for Celgene Corp /de/. You might contact Celgene Corp /de/ via mailing address: 86 Morris Avenue, Summit Nj 07901.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.